Cozaar
The Primary endpoint of the analysis was a comparison for four weeks patient, which reached target diastolic blood pressure (the feeding trough, sitting DBP <90 mmHg) on HYZAAR 50-12.5 mg. against patient on COZAAR (losartan tablets potassium) 50 mg titrated on 100 mg. as needed to reach target diastolic blood pressure. The Results learns at week four shown:
– Average reduction in diastolic pressure was 13.6 mmHg for patient, HYZAAR vs. 10.5 mmHg during that taking COZAAR, difference 3.1 reduce mmHg for that addressed HYZAAR.
– Average reduction in systolic pressure was 18.0 mmHg during that taking HYZAAR vs. 12.4 mmHg for on COZAAR, difference 5.6 mmHg for that addressed HYZAAR.
As a result, big proportion patient on HYZAAR reached target diastolic blood pressure (17.6 percent for HYZAAR, 9.4 percent for COZAAR; p=0.006). The Similar directions were seen when patients were grouped according to sort, racing or age (less than 65 and 65 or more old).
The Secondary endpoint was a comparison on poles week patient, which reached target diastolic blood pressure in HYZAAR 50-12.5 mg titrated as needed HYZAAR 100-25 vs patient mg. in mg COZAAR 50 titrated on 100 mg. and then in 150 mg. The Results learns at week poles shown:
– Average reduction in diastolic pressure was 17.8 mmHg for patient, HYZAAR vs. 11.9 mmHg during that taking COZAAR.
– Average reduction in systolic pressure was 25.1 mmHg during that taking HYZAAR vs. 14.1 mmHg for on COZAAR.
On poles week, more patient HYZAAR target diastolic blood pressure addressed in group than that addressed COZAAR (29.8 percent 12.5 percent vs.).
“In clinical analysis, supporting this new instruction, we saw that more patient with serious hypertension their diastolic blood pressure, reducing purpose less than 90 mmHg for four weeks with HYZAAR in contrast with titrated in more high doses COZAAR,” said Dr. Bakris.
In clinical test, the processing with HYZAAR usually was well tolerated. In clinical analysis, supporting this new instruction, the general profile of the side effect for patient with serious hypertension addressed HYZAAR as initial therapy was like profile of the side effect on patient with serious hypertension addressed COZAAR as initial therapy. For period of the analysis was not no registered events of the syncope in any group of the processing. There were two events (0.6 percent) and no events hypotension registered in group addressed HYZAAR and COZAAR, accordingly. There were three events (0.8 percent) and two events (1.2 percent) raised wheys creatinine (> 0.5 mg./dl) in group addressed HYZAAR and COZAAR, accordingly.
In other clinical test, the general incidence disadvantage event with losartan kaliem-hydrochlorothiazide was comparable to Most general disadvantage events, coming of different dose losartan kaliya-hydrochlorothiazide (n=858) at a rate of one percent or more said (n=173) were an upper infection respiratory (6 percents 5 percents vs.), dizziness (6 percents 3 percents vs.), pain (2 percents vs. 1 percent), thrill (1 percent vs. 0 percents) and rash (1 percent vs. 0 percents).
When is used in pregnancy during the second or the third trimester, medicine, which act right in renin-system angiotensin can cause the damage and even death in devising fetus. When pregnancy is discovered, COZAAR and HYZAAR must stop at earliest convenience.
COZAAR And HYZAAR contraindicated on patient, which supersensitive in any component of these products. Because of component hydrochlorothiazide, HYZAAR also contraindicated on patient with anuria (the absence of the forming the urine) or hypersensitivity in other sulfonamide- derived medicine. HYZAAR is NOT recommended for patient with serious kidney deterioration (creatinine clearance = 30mL/min) or as facility titration for patient with liver deterioration. HYZAAR is NOT recommended for use as initial therapy on patient with intravascular volume depletion (eg., that addressed by diuretics). All patients, getting thiazides must be for clinical sign fluid or imbalance of the electrolyte, including hypokalemia. Either as the other medicine, which block angiotensin II or effects, use the concomitant potassium-moderate diuretics, additions potassium, or salty change, containing potassium can conduct to increase in potassium of the whey.
Starting dose HYZAAR for initial processing the serious hypertension - one tablet HYZAAR 50-12.5 mg. as soon as daily. For patient who does not acceptable on HYZAAR 50-12.5 mg. after two for four weeks therapy, dosage can be increased in one tablet HYZAAR 100-25 mg. as soon as daily. The Maximum dose is one tablet HYZAAR 100-25 mg. as soon as daily. HYZAAR is NOT recommended as initial therapy on patient with liver deterioration since approaching 25 mg. starting dose losartan not to can to be given.
Usually starting dose COZAAR on patient with hypertension - COZAAR 50 mg. as soon as daily. The Maximum daily dose - 100 mg. If effect antihypertensive measured in use the feeding trough as toliko-a-day dosing will be inadequate, dvazhdy-a-day mode in same general daily dose or increase in dose can give the more satisfactory answer. 150 Mg. doses COZAAR are not shown to give the better performance than 50 mg. or 100 mg. On patient, which - a volume-exhausted, symptomatic hypotension to can to occur after initiation therapy with COZAAR. This condition must be updated before administration COZAAR, or dosage COZAAR 25 mg. must be used. On patient with historian of the liver deterioration, starting dose COZAAR 25 mg. must be used.
The Patients, whose blood pressure did not finish monotherapy with COZAAR or hydrochlorothiazide only can be switched to HYZAAR 50-12.5 mg. as soon as daily. If blood pressure remains uncontrolled, physicians can titrate on HYZAAR 100-25 mg. as soon as daily.
Chosen important information on HYZAAR and COZAAR When is used in pregnancy during the second or the third trimester, medicine, which act right in renin-system angiotensin can cause the damage and even death in devising fetus. When pregnancy is discovered, COZAAR and HYZAAR must stop at earliest convenience.
COZAAR And HYZAAR contraindicated on patient, which supersensitive in any component of these products. Because of component hydrochlorothiazide, HYZAAR also contraindicated on patient with anuria (the absence of the forming the urine) or hypersensitivity in other sulfonamide- derived medicine.
HYZAAR is NOT recommended for patient with serious kidney deterioration (creatinine clearance <30mL/min). HYZAAR is NOT recommended for titration for patient with liver deterioration since approaching 25 mg. starting dose COZAAR not to can to be given. On patient, which exhausted volume (eg., that addressed by diuretics), symptomatic hypotension to can to occur after initiation therapy with HYZAAR. This condition must be updated before administration HYZAAR. All patients, getting thiazides must be for clinical sign fluid or imbalance of the electrolyte, including hypokalemia.
On patient, which - a volume-exhausted, symptomatic hypotension to can to occur after initiation therapy with COZAAR. This condition must be updated before administration COZAAR, or dosage COZAAR 25 mg. must be used. On patient with historian of the liver deterioration, starting dose COZAAR 25 mg. must be used. Either as the other medicine, which block angiotensin II or effects, use the concomitant potassium-moderate diuretics, additions potassium, or salty change, containing potassium can conduct to increase in potassium of the whey.
In other clinical test with losartan for hypertension, most general disadvantage events with incidence greater or equal two percents patient addressed COZAAR (n=1,075) and occurring more usually than (n=334) included upper infection respiratory (8 percents for losartan 7 percents vs for dizziness (3 percents for losartan 2 percents vs for nose overloading (2 percents for losartan vs. 1 percent for and inverse pain (2 percents for losartan vs. 1 percent for.
In other clinical test with losartan kaliem-hydrochlorothiazide, the general incidence disadvantage event was comparable to Most general disadvantage events, coming of different dose losartan kaliya-hydrochlorothiazide (n=858) at a rate of one percent or more said (n=173) were an upper infection respiratory (6.1 percent 4.6 percent vs.), dizziness (5.7 percent 2.9 percent vs.), cough (2.6 percent 2.3 percent vs.), pain (2.1 percent 0.6 percent vs.), thrill (1.4 percent vs. 0 percents) and rash (1.4 percent vs. 0 percents).
In clinical analysis, supporting initial therapy instruction, the general profile of the side effect for patient with serious hypertension addressed HYZAAR as initial therapy was like profile of the side effect on patient with serious hypertension addressed COZAAR as initial therapy. For period of the analysis was not no registered events of the syncope in any group of the processing. There were two events (0.6 percent) and no events hypotension registered in group addressed HYZAAR and COZAAR, accordingly. There were three events (0.8 percent) and two events (1.2 percent) raised wheys creatinine (> 0.5 mg./dl) in group addressed HYZAAR and COZAAR, accordingly, during the same length of time.
